New York is currently home to 4503 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New York, Rochester, Bronx and Buffalo. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
DB-3Q bmMSC-EVs in Patients With Perianal Fistulizing Crohn's Disease
Recruiting
This is a double-blind, randomized, placebo-controlled, sequential cohort, ascending dose clinical trial to evaluate the safety and determine the efficacy of ascending doses of DB-3Q for the treatment of Perianal Fistulizing Crohn's Disease.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
06/13/2025
Locations: Columbia University Irving Medical Center/NYPH, New York, New York
Conditions: Perianal Fistula Due to Crohn's Disease
Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age
Recruiting
This study is a Phase 3, randomized, modified double-blind study which aims to measure whether the investigational pneumococcal conjugate vaccine PCV21 is safe and can help the body to develop germ-fighting agents called "antibodies" (immunogenicity) when it is given after 1 dose, 2 doses, or 3 doses of a licensed 20-valent pneumococcal vaccine compared to when 20-valent pneumococcal vaccine is given as a complete series in infants aged from approximately 2 months (42 to 89 days). The study dur... Read More
Gender:
ALL
Ages:
Between 42 days and 89 days
Trial Updated:
06/13/2025
Locations: ~SUNY Upstate Medical University- Site Number : 8400015, Syracuse, New York
Conditions: Pneumococcal Immunization
A Study of MGC028 in Participants With Advanced Solid Tumors
Recruiting
The goal of this clinical trial is to characterize the safety, tolerability, dose-limiting toxicities (DLT), and maximum tolerated dose (MTD) or maximum administered dose of MGC028 (if no MTD is defined). The study will enroll adult participants with relapsed or refractory, unresectable, locally advanced of metastatic solid tumors known to express ADAM9. The main question the study aims to answer is: * What types of side effects will participants experience when receiving MGC028? * Can MGC028... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/13/2025
Locations: Icahn School of Medicine at Mt. Sinai, New York, New York
Conditions: Advanced Solid Tumors, NSCLC Adenocarcinoma, Cholangiocarcinoma, Pancreatic Carcinoma, Colorectal Carcinoma
A Study of Glofitamab and Lenalidomide in People With Mantle Cell Lymphoma
Recruiting
The purpose of this study is to find out whether the combination of glofitamab and lenalidomide is an effective treatment for relapsed or refractory Mantle Cell Lymphoma
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/13/2025
Locations: Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities), Commack, New York
Conditions: Mantle Cell Lymphoma, MCL
A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease
Recruiting
Crohn's Disease (CD) is a gastrointestinal disease that can cause chronic diarrhea with or without gross bleeding, abdominal pain, weight loss, and fever. This study will assess the pharmacokinetics, efficacy, and safety of risankizumab in pediatric participants with moderately to severely active CD aged 2 to \< 18 years old who have had intolerance or inadequate response to other therapies. Risankizumab is an approved drug for adults with plaque psoriasis, psoriatic arthritis, and CD and is be... Read More
Gender:
ALL
Ages:
Between 2 years and 17 years
Trial Updated:
06/13/2025
Locations: Icahn School of Medicine at Mount Sinai /ID# 254880, New York, New York
Conditions: Crohn's Disease
A Dose Escalation Study of AV-380 in Cancer Patients With Cachexia
Recruiting
This open label ascending dose study is designed to evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of AV-380 in cancer patients with Cachexia. AV-380 is an immunoglobulin (Ig) G1 monoclonal antibody (mAb) intended to bind circulating human growth differentiation factor 15 (GDF-15), a cytokine involved in cancer-induced cachexia.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/13/2025
Locations: New York Cancer And Blood Specialists, Shirley, New York
Conditions: Cachexia
A Study of Tumor-Treating Fields (TTFields) in People With Lung Adenocarcinoma
Recruiting
The researchers are doing this study to find out if treatment with TTFields using the NovoTTF-200T System is safe and practical (feasible) before surgical removal (resection) of lung adenocarcinoma (ADC). The researchers will also look at how the treatment may help the body's immune system to fight cancer.
Gender:
ALL
Ages:
22 years and above
Trial Updated:
06/13/2025
Locations: Memorial Sloan Kettering Suffolk - Commack (Consent Only), Commack, New York
Conditions: Adenocarcinoma of Lung
A Study to Investigate Why Overweight People Regain Weight After Losing Weight in a Behavioral Weight Loss Program
Recruiting
The goal of this clinical trial is to determine the physiological basis for the differences in weight regain among adults (25-59 years old) with obesity following participation in a behavioral weight loss program. Eligible participants will undergo a baseline evaluation after which they will enter an up to 20 week behavioral weight loss program with the goal of losing at least 7 percent of their baseline weight within 35 weeks. Participants who meet the weight loss goal will be asked to remain w... Read More
Gender:
ALL
Ages:
Between 25 years and 59 years
Trial Updated:
06/13/2025
Locations: Columbia University Irving Medical Center, New York, New York
Conditions: Obesity
Doxycycline for Emphysema in People Living With HIV (The DEPTH Trial)
Recruiting
The purpose of this study is to determine if doxycycline will reduce progression of emphysema in people living with HIV. The secondary objectives are to examine the effects of doxycycline on change in quantity of emphysema, six minute walk distance, patient reported outcomes, ratio of forced expiratory volume in 1 second and forced vital capacity. Secondary objectives will also describe the safety and tolerability of doxycycline and determine if doxycycline is associated with development of ant... Read More
Gender:
ALL
Ages:
30 years and above
Trial Updated:
06/13/2025
Locations: SUNY Downstate Medical School, Brooklyn, New York
Conditions: Emphysema, HIV
A Phase I/IIa Study of AZD8205 Given Alone or in Combination With Anticancer Drugs, in Participants With Advanced or Metastatic Solid Malignancies
Recruiting
This research study is studying a new compound, AZD8205, as a possible treatment for advanced or metastatic solid tumours alone or in combination with anti-cancer agents
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/13/2025
Locations: Research Site, Commack, New York
Conditions: Breast Cancer, Ovarian Cancer, Endometrial Cancer, Biliary Tract Carcinoma, Squamous Non-Small Cell Lung Cancer
Clarifying the Optimal Application of SLT Therapy Trial
Recruiting
The goal of this study is to understand if SLT performed at low energy is as effective as SLT performed at standard energy, and also to see if repeating SLT at low energy once a year will prevent or delay the need for daily eye drop medications better than waiting for SLT to wear off before repeating it.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/13/2025
Locations: New York Eye Surgery Associates, Bronx, New York
Conditions: Glaucoma and Ocular Hypertension
Post Approval Study - Evaluate the Long-Term Safety and Effectiveness of the WEB Device
Recruiting
A prospective, multicenter, single arm, interventional study. The target patient population for this study are adult subjects with WNBAs of the anterior and posterior intracranial circulation. The primary effectiveness outcome of the study is adequate intracranial aneurysm occlusion on the 1 year angiogram as adjudicated by a core laboratory.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/13/2025
Locations: Albany Medical Center, Albany, New York
Conditions: Wide Neck Bifurcation Intracranial Aneurysms